Asset Details
Do you wish to reserve the book?
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
Do you wish to request the book?
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
2007
Overview
Palliative imatinib treatment has dramatically improved survival in patients with malignant gastrointestinal stromal tumours, particularly in patients with tumours harbouring activating
KIT
mutations. To evaluate the effectiveness of adjuvant imatinib after radical surgery, a consecutive series of patients with high-risk tumours (
n
=23) was compared with historic controls (
n
=48) who were treated with surgery alone. The mean follow-up period was over 3 years in both groups. Only 1 out of 23 patients (4%) in the adjuvant treatment group developed recurrent disease compared to 32 out of 48 patients (67%) in the control group. This preliminary study indicates that 1 year of adjuvant treatment with imatinib dramatically improves recurrence-free survival. Confirmation of these findings awaits the results of ongoing randomised studies.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adjuvant
/ Adult
/ Aged
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Female
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Gastrointestinal Stromal Tumors - diagnosis
/ Gastrointestinal Stromal Tumors - drug therapy
/ Gastrointestinal Stromal Tumors - genetics
/ Gastrointestinal Stromal Tumors - surgery
/ Gastrointestinal Stromal Tumors/diagnosis/drug therapy/genetics/surgery
/ Humans
/ Male
/ Oncology
/ Piperazines - therapeutic use
/ Pyrimidines - therapeutic use
/ Receptor Protein-Tyrosine Kinases - genetics
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
/ Tumors
